A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)-Reference-Cited by-同舟云学术

A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)

Published:2024-06-24 Issue:1 Volume:13 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Lee Dong Ki¹,Park Sook Ryun²,Kim Yeul Hong³,Lee Yun-Gyoo⁴,Shin Su-Jin⁵,Ahn Beung-Chul⁶,Lee Sung Sook⁷,Lim Sun Min⁸,Kim Hye Ryun⁸,Cho Byoung Chul⁸,Hong Min Hee⁸^ORCID

Affiliation:

1. Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea

2. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

3. Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea

4. Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

5. Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

6. Center for Lung Cancer, National Cancer Center, Goyang-si, South Korea

7. Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea

8. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

Funder